GW Pharmaceuticals’ cannabis-derived epilepsy drug wins European approval
The European Commission approved GW Pharma's Epidyolex as a treatment for seizures in two rare and severe forms of epilepsy. The drug won FDA approval last year.
The European Commission approved GW Pharma's Epidyolex as a treatment for seizures in two rare and severe forms of epilepsy. The drug won FDA approval last year.
The drug showed positive results in a 210-patient study in patients experiencing treatment-resistant seizures from tuberous sclerosis complex, a rare form of epilepsy.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.